Mortality and its determinants in people with psychotic disorder

Psychosomatic Medicine

Volumn 75, Issue 1, 2013, Pages 60-67

  Suvisaari, Jaana ^a   Partti, Krista ^a   Perälä, Jonna ^a   Viertiö, Satu ^a   Saarni, Suoma E ^a   Lönnqvist, Jouko ^a   Saarni, Samuli I ^a   Härkänen, Tommi ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

antipsychotic medication; mortality; psychotic disorders; schizophrenia; smoking; Type 2 diabetes

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AFFECTIVE PSYCHOSIS; ARTICLE; BIPOLAR I DISORDER; BRIEF PSYCHOTIC DISORDER; COMORBIDITY; CONTROLLED STUDY; DELUSIONAL DISORDER; DISEASE ASSOCIATION; DISEASE REGISTRY; DSM-IV; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL RECORD REVIEW; MENTAL HEALTH CARE; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SENSITIVITY AND SPECIFICITY; SMOKING; SOCIAL STATUS; STRUCTURED INTERVIEW;

EID: 84872337035     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0b013e31827ad512     Document Type: Article

References (46)

1. Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Mental disorders and cause-specific mortality. Br J Psychiatry 2001;179: 498-502.
2. Heilä H, Haukka J, Suvisaari J, Lönnqvist J. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med 2005;35:725-32.
3. Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 2007;68:899-907.
4. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31.
5. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-7.
6. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010;196:116-21.
7. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007;64:242-9.
8. Kilbourne AM, Morden NE, Austin K, Ilgen M, McCarthy JF, Dalack G, Blow FC. Excess heart-diseaseYrelated mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry 2009;31:555-63.
9. Kelly DL, McMahon RP, Wehring HJ, Liu F, Mackowick KM, Boggs DL, Warren KR, Feldman S, Shim JC, Love RC, Dixon L. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull 2011;37: 832-8.
10. Suvisaari J, Perälä J, Saarni SI, Härkänen T, Pirkola S, Joukamaa M, Koskinen S, Lönnqvist J, Reunanen A. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. Eur Arch Psychiatry Clin Neurosci 2008; 258:129-36.
11. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Mö ller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S. Physical illness in patients with severe mental disorders, I: Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77.
12. Suvisaari JM, Saarni SI, Perälä J, Suvisaari JVJ, Härkänen T, Lönnqvist J, Reunanen A. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007;68:1045-55.
13. Saarni SE, Saarni SI, Fogelholm M, Heliövaara M, Perälä J, Suvisaari J, Lönnqvist J. Body composition in psychotic disordersVa general population survey. Psychol Med 2009;39:801-10.
14. Viertiö S, Sainio P, Koskinen S, Perälä J, Saarni SI, Sihvonen M, Lönnqvist J, Suvisaari J. Mobility limitations in persons with psychotic disorder: findings from a population-based survey. Soc Psychiatry Psychiatr Epidemiol 2009;44:325-32.
15. Suvisaari J, Perälä J, Saarni SI, Kattainen A, Lönnqvist J, Reunanen A. Coronary heart disease and cardiac conduction abnormalities in persons with psychotic disorders in a general population. Psychiatry Res 2010; 175:126-32.
16. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011;68:609-16.
17. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8:114-26.
18. Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010; 71:103-8.
19. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43.
20. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41.
21. Perälä J, Saarni SI, Ostamo A, Pirkola S, Haukka J, Härkänen T, Koskinen S, Lönnqvist J, Suvisaari J. Geographic variation and sociodemographic characteristics of psychotic disorders in Finland. Schizophr Res 2008; 106:337-47.
22. Blomgren J, Martikainen P, Grundy E, Koskinen S. Marital history 1971-91 and mortality 1991-2004 in England & Wales and Finland. J Epidemiol Community Health 2012;66:30-6.
23. van Raalte AA, Kunst AE, Lundberg O, Leinsalu M, Martikainen P, Artnik B, Deboosere P, Stirbu I, Wojtyniak B, Mackenbach JP. The contribution of educational inequalities to lifespan variation. Popul Health Metr 2012;10:3.
24. World Health Organization. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva: World Health Organization; 2009. Available at http://www.who.int/healthinfo/global-burden-disease/ GlobalHealthRisks-report-full.pdf. Accessed March 12, 2012.
25. Wildgust HJ, Hodgson R, Beary M. The paradox of premature mortality in schizophrenia: new research questions. J Psychopharmacol 2010;24:9-15.
26. Aromaa A, Koskinen S, editors. Health and Functional Capacity in Finland. Baseline Results of the Health 2000 Health Examination Survey. Publications of the National Public Health Institute B12; 2004. Available (in English) at http://www.terveys2000.fi/julkaisut/baseline.pdf. Accessed March 12, 2012.
27. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I DisordersVPatient Edition (SCID I/P, 2/2001 Revision). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 2001.
28. Wittchen HU, Lachner G,Wunderlich U, Pfister H. Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI). Soc Psychiatry Psychiatr Epidemiol 1998; 33:568-78.
29. Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, Kieseppä T, Härkänen T, Koskinen S, Lönnqvist J. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007;64:19-28.
30. Kendler KS, McGuire M, Gruenberg AM,Walsh D. Clinical heterogeneity in schizophrenia and the pattern of psychopathology in relatives: results from an epidemiologically based family study. Acta Psychiatr Scand 1994;89:294-300.
31. Perälä J, Kuoppasalmi K, Pirkola S, Härkänen T, Saarni S, Tuulio-Henriksson A, Viertiö S, Latvala A, Koskinen S, Lönnqvist J, Suvisaari J. Alcohol-induced psychotic disorder and delirium in the general population. Br J Psychiatry 2010;197:200-6.
32. World Health Organization Expert Committee. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Report of a WHO Consultation, I: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization; 1999.
33. Kattainen A, Salomaa V, Härkänen T, Jula A, Kaaja R, Kesäniemi YA, Kähönen M, Moilanen L, Nieminen MS, Aromaa A, Reunanen A. Coronary heart disease: from a disease of middle-aged men in the late 1970s to a disease of elderly women in the 2000s. Eur Heart J 2006;27:296-301.
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
35. Jakobsen LH, Rask IK, Kondrup J. Validation of handgrip strength and endurance as a measure of physical function and quality of life in healthy subjects and patients. Nutrition 2010;26:542-50.
36. Ling CH, Taekema D, de Craen AJ, Gussekloo J, Westendorp RG, Maier AB. Handgrip strength and mortality in the oldest old population: the Leiden 85-plus study. CMAJ 2010;182:429-35.
37. Markkula N, Härkänen T, Perälä J, Partti K, Peña S, Koskinen S, Lönnqvist J, Suvisaari J, Saarni SI. Mortality in people with depressive, anxiety and alcohol use disorders in Finland. Br J Psychiatry 2012;200:143-9.
38. Schmidt LM, Hesse M, Lykke J. The impact of substance use disorders on the course of schizophreniaVa 15-year follow-up study: dual diagnosis over 15 years. Schizophr Res 2011;130:228-33.
39. Lunetta P, Lounamaa A, Sihvonen S. Surveillance of injury-related deaths: medicolegal autopsy rates and trends in Finland. Inj Prev 2007;13:282-4.
40. Chang CK, Hayes RD, Perera G, Broadbent MT, Fernandes AC, Lee WE, Hotopf M, Stewart R. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS One 2011;6:e19590.
41. Partti K, Heliövaara M, Impivaara O, Perälä J, Saarni SI, Lönnqvist J, Suvisaari J. Skeletal status in psychotic disorders: a population-based study. Psychosom Med 2010;72:933-40.
42. Viertiö S, Tuulio-Henriksson A, Perälä J, Saarni SI, Koskinen S, Sihvonen M, Lönnqvist J, Suvisaari J. Activities of daily living, social functioning and their determinants in persons with psychotic disorder. Eur Psychiatry 2012;27:409-15.
43. Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio RV, Ganoczy D, Cunningham F, Schneider LS, Blow FC. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry 2011;68:190-7.
44. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, NjLlstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-41.
45. Schoepf D, Potluri R, Uppal H, Natalwala A, Narendran P, Heun R Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up. Eur Psychiatry 2012;27:33-42.
46. Mayer-Davis EJ, Costacou T. Obesity and sedentary lifestyle: modifiable risk factors for prevention of type 2 diabetes. Curr Diab Rep 2001;1:170-6.